MICA: Therapy for the body and breath malodour disorder Trimethylaminuria (TMAU)

MICA:治疗身体和呼吸异味障碍三甲胺尿 (TMAU)

基本信息

  • 批准号:
    MR/K015494/1
  • 负责人:
  • 金额:
    $ 45.96万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2013
  • 资助国家:
    英国
  • 起止时间:
    2013 至 无数据
  • 项目状态:
    已结题

项目摘要

Trimethylaminuria (TMAU) is a disorder in which affected people suffer from severe body odour often accompanied by severe bad breath. The disorder arises because of mutations in a gene called FMO3 and not because of poor hygiene. Why do changes in the FMO3 gene cause body and breath odour? When we eat food that contains choline (which many foods do, e.g. red meat, seafood, some vegetables, soya, eggs and chocolate) then the bacteria that live in our gut cause the problem. The bacteria break choline down to produce a small molecule called trimethylamine. This chemical is the one to which the human nose is most sensitive and which is also the chemical that gives rotting fish its characteristic smell. In people with a normal FMO3 gene there is no odour problem because the FMO3 enzyme we have in our liver changes trimethylamine into a chemical that does not smell. BUT, if the FMO3 enzyme cannot do this, then the trimethylamine is not changed and is excreted in urine, sweat and breath. Social isolation, ridicule and limited employment prospects are experienced by those with TMAU, this usually means a low quality of life; high levels of depression, suicide and divorce occur in this population. Our study will test a therapy for TMAU that will reduce the amount of urinary trimethylamine excreted. Our pre-clinical findings will prepare the way for clinical studies in humans in the future. A reduction in body and breath odour will contribute greatly to an improved quality of life for those with TMAU.
三甲基氨基尿症(TMAU)是一种疾病,其中受影响的人患有严重的体臭,通常伴有严重的口臭。这种疾病的发生是因为一种叫做FMO 3的基因突变,而不是因为卫生条件差。为什么FMO 3基因的变化会导致身体和呼吸气味?当我们吃含有胆碱的食物(许多食物都含有胆碱,例如红肉,海鲜,一些蔬菜,大豆,鸡蛋和巧克力)时,生活在我们肠道中的细菌就会引起问题。这种细菌分解胆碱产生一种叫做三甲胺的小分子。这种化学物质是人类鼻子最敏感的化学物质,也是使腐烂的鱼具有其特有气味的化学物质。在正常FMO 3基因的人中,没有气味问题,因为我们肝脏中的FMO 3酶将三甲胺转化为没有气味的化学物质。但是,如果FMO 3酶不能做到这一点,那么三甲胺不会改变,并通过尿液,汗液和呼吸排出体外。社会孤立,嘲笑和有限的就业前景所经历的那些与TMAU,这通常意味着低生活质量;高水平的抑郁症,自杀和离婚发生在这个人群。我们的研究将测试一种治疗TMAU的方法,该方法将减少尿中三甲胺的排泄量。我们的临床前研究结果将为未来的人类临床研究铺平道路。减少身体和呼吸气味将大大有助于改善TMAU患者的生活质量。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of Flavin-Containing Monooxygenase Genotype, Mouse Strain, and Gender on Trimethylamine N-oxide Production, Plasma Cholesterol Concentration, and an Index of Atherosclerosis.
Clinical utility gene card for: Trimethylaminuria - update 2014.
A highly sensitive liquid chromatography electrospray ionization mass spectrometry method for quantification of TMA, TMAO and creatinine in mouse urine.
  • DOI:
    10.1016/j.mex.2017.09.004
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    1.9
  • 作者:
    Veeravalli S;Karu K;Phillips IR;Shephard EA
  • 通讯作者:
    Shephard EA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth Shephard其他文献

P112 Partnering for Community-Health and Wellness: A County-Wide, Mayor's Fitness Challenge
  • DOI:
    10.1016/j.jneb.2021.04.454
  • 发表时间:
    2021-07-01
  • 期刊:
  • 影响因子:
  • 作者:
    Angelika Keene;Elizabeth Shephard
  • 通讯作者:
    Elizabeth Shephard
The conditional associations between neurodevelopmental traits, social-environmental stressors, and emotional dysregulation in childhood and depressive symptoms over development: a Bayesian multivariate analysis of two UK cohorts
神经发育特征、社会环境压力源和儿童期情绪失调与发育过程中抑郁症状之间的条件关联:对两个英国队列的贝叶斯多变量分析
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Farhat;Luis;Rachel Blakey;G. Davey;Anita Polanczyk;Luis C. Farhat;Smith;Prof. André Fujita;Elizabeth Shephard;E. Stergiakouli;C. Prof.Thalia;Eley;Prof. Anita Thapar;Prof. Guilherme;V. Polanczyk;V. Prof.Guilherme;Polanczyk
  • 通讯作者:
    Polanczyk
Flavin-containing monooxygenase 3 (FMO3) genotype and phenotype in a Japanes e cohort
日本 e 队列中的含黄素单加氧酶 3 (FMO3) 基因型和表型
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Makiko Shimizu;Elizabeth Shephard;Ian R. Phillips;Hiroshi Yamazaki
  • 通讯作者:
    Hiroshi Yamazaki
Learning and altering behaviours by reinforcement: Neurocognitive differences between children and adults
通过强化学习和改变行为:儿童和成人之间的神经认知差异
3.83 Early-Life Correlates of 3-Month-Old Infants’ Negative Affect: An Analysis of the Brainrise Study
  • DOI:
    10.1016/j.jaac.2022.09.362
  • 发表时间:
    2022-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Tatiane Neves Borja;Guilherme Vanoni Polanczyk;Elizabeth Shephard;Daniel Fatori
  • 通讯作者:
    Daniel Fatori

Elizabeth Shephard的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Heat therapy for the treatment of SCI-induced changes in nociceptor and mitochondrial function
热疗法治疗 SCI 引起的伤害感受器和线粒体功能变化
  • 批准号:
    10641385
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
Preclinical testing of early life anti-myostatin therapy for osteogenesis imperfecta
早期抗肌生长抑制素治疗成骨不全症的临床前测试
  • 批准号:
    10840238
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
Glucagon Pump Therapy for Post-Bariatric Hypoglycemia: Merging Physiology and Engineering
胰高血糖素泵治疗减肥后低血糖:生理学与工程学的结合
  • 批准号:
    10754041
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
Engineered tissue arrays to streamline deimmunized DMD gene therapy vectors
工程组织阵列可简化去免疫 DMD 基因治疗载体
  • 批准号:
    10724882
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
Development of peptide drug conjugates for cancer therapy
开发用于癌症治疗的肽药物缀合物
  • 批准号:
    10760236
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
Amnion cell secretome mediated therapy for traumatic brain injury
羊膜细胞分泌组介导的创伤性脑损伤治疗
  • 批准号:
    10746655
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
Pulmonary endothelium targeted adenoviral gene therapy for the correction of mucopolysaccharidosis type I
肺内皮靶向腺病毒基因治疗纠正 I 型粘多糖贮积症
  • 批准号:
    10678053
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
New Therapy for the Treatment of Primary Biliary Cholangitis.
治疗原发性胆汁性胆管炎的新疗法。
  • 批准号:
    10697484
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
IND-enabling studies for cell therapy in Parkinson's disease
帕金森病细胞疗法的 IND 研究
  • 批准号:
    10760861
  • 财政年份:
    2023
  • 资助金额:
    $ 45.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了